| Literature DB >> 27707957 |
Yan Ding1, Xiao-Li Xiong2, Li-Shan Zhou2, Su-Qi Yan2, Huan Qin3, Hua-Rong Li4, Ling-Ling Zhang2, Peng Chen5, Cong Yao6, Zhi-Xia Jiang2, Lei Zhao7.
Abstract
The aim of this study is to investigate Emodin on alleviating intrahepatic cholestasis by regulation of liver farnesoid X receptor (FXR) pathway. Cell and animal models of intrahepatic cholestatis were established. Biochemical tests and histomorphology were performed. The messenger RNA (mRNA) and protein expression of FXR, small heterodimer partner (SHP), uridine diphosphate glucuronosyltransferase 2 family polypeptide B4 (UGT2B4), and bile salt export pump (BSEP) was detected. As a result, compared with the model group, the serum levels of biochemical test were significantly lower in the Emodin group (P <0.01). The histopathological changes were remitted significantly by Emodin treatment. In the model group, the mRNA and protein expression of FXR, SHP, UGT2B4, and BSEP was significantly lower than in the normal group in cell models (P <0.05). With Emodin intervention, the expression of FXR, SHP, UGT2B4, and BSEP was notably increased (P <0.05). In conclusion, Emodin plays a protective role in intrahepatic cholestasis by promoting FXR signal pathways.Entities:
Keywords: Emodin; farnesoid X receptor (FXR); intrahepatic cholestasis; α-naphthyl isothiocyanate
Mesh:
Substances:
Year: 2016 PMID: 27707957 PMCID: PMC5806847 DOI: 10.1177/0394632016672218
Source DB: PubMed Journal: Int J Immunopathol Pharmacol ISSN: 0394-6320 Impact factor: 3.219